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Optic neuritis (ON) is a recognized condition, yet factors influencing recovery of
vision are currently unknown. The purpose of this study was to identify prognostic
factors for recovery of vision in canine ON of unknown etiology. Clinical databases
of three referral hospitals were searched for dogs with presumptive ON based on
clinicopathologic, MRI/CT, and fundoscopic findings. Twenty-six dogs diagnosed with
presumptive ON of unknown etiology, isolated (I-ON) and MUE-associated (MUE-ON),
were included in the study. Their medical records were reviewed retrospectively, and the
association of complete recovery of vision with signalment, clinicopathologic findings,
and treatment was investigated. Datasets were tested for normality using the D’Agostino
and Shapiro-Wilk tests. Individual datasets were compared using the Chi-squared
test, Fisher’s exact test, and the Mann-Whitney U-test. For multiple comparisons
with parametric datasets, the one-way analysis of variance (ANOVA) was performed,
and for non-parametric datasets, the Kruskal-Wallis test was performed to test for
independence. For all data, averages are expressed as median with interquartile range
and significance set at p < 0.05. Twenty-six dogs met the inclusion criteria. Median
follow-up was 230 days (range 21–1901 days, mean 496 days). Six dogs (23%) achieved
complete recovery and 20 dogs (77%) incomplete or no recovery of vision. The presence
of a reactive pupillary light reflex (p = 0.013), the absence of fundoscopic lesions
(p = 0.0006), a younger age (p = 0.038), and a lower cerebrospinal fluid (CSF) total
nucleated cell count (TNCC) (p = 0.022) were statistically associated with complete
recovery of vision. Dogs with I-ON were significantly younger (p = 0.046) and had lower
CSF TNCC (p= 0.030) compared to the MUE-ON group. This study identified prognostic
factors that may influence complete recovery of vision in dogs with ON. A larger cohort of
dogs is required to determine whether these findings are robust and whether additional
parameters aid accurate prognosis for recovery of vision in canine ON.
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INTRODUCTION
Optic neuritis (ON) is a general term describing the pathological
process of optic nerve inflammation and represents a clinical
syndrome more than a specific disease (1, 2). Clinical signs are
typically characterized by acute, bilateral or unilateral, partial
or complete loss of vision (1, 3). Papillitis and neuroretinitis
can be detected on fundoscopic examination (3–5) while
retrobulbar ON generally lacks ophthalmoscopic abnormalities
(1, 6, 7). Classification focuses on the underlying etiology
in veterinary medicine. Presumed immune-mediated (5–13),
neoplastic (1, 5, 14–19) and infectious diseases (5, 20–34)
have been reported in association with ON. Other causes
include extension of inflammation/infection and neoplasia from
neighboring anatomical structures (1, 8, 14, 35), trauma (36), and
toxins (5, 37, 38).
Canine ON of unknown etiology is believed to be immune-
mediated. It is traditionally attributed to a focal form of
granulomatous meningoencephalomyelitis (GME) or is
considered part of a multifocal central nervous system (CNS)
lesion-distribution of the same disease (6, 9, 10, 14, 39–42).
Optic neuritis has also been reported in a dog with necrotizing
leukoencephalitis (NLE) (1, 43). Both GME and NLE fall
under the same umbrella term “meningoencephalomyelitis
of unknown etiology (MUE)” but comprise disorders with
clinicopathologic differences (11, 44–50). Definitive diagnosis
requires histopathological examination (11, 44, 47, 51–53).
In people, several pathogenetic theories have been proposed,
and ON has been subdivided in typical and atypical forms (2).
Optic neuritis is usually ascribed to multiple sclerosis (MS), and
isolated forms are considered potential precursors of this disease
(54). Other atypical causes of immune-mediated ON include
neuromyelitis optica (NMO), neuromyelitis optica spectrum
disorders (NMOSD), acute disseminated encephalomyelitis
(ADEM), chronic recurrent immune optic neuropathy and
autoimmune diseases with secondary optic nerve involvement
(2, 55). These subtypes are characterized by distinct clinical
courses and therapeutic requirements (2). Similarly, variations
in the clinicopathologic presentation and outcome have been
reported in dogs with idiopathic ON (5). There is currently no
information available to classify canine ON cases as different
phenotypic variants/stages of the same etiopathogenic entity or
separate diseases.
Abbreviations: ON, optic neuritis; CNS, central nervous system; GME,
granulomatous meningoencephalomyelitis; NLE, necrotizing leukoencephalitis;
MUE, meningoencephalomyelitis of unknown etiology; PLR, pupillary light
reflex; CSF, cerebrospinal fluid; TNCC, total nucleated cell count; CT, computed
tomography; MRI, magnetic resonance imaging; ERG, electroretinography;
FLAIR, fluid-attenuated inversion recovery; STIR, short tau inversion recovery;
MUE-ON, MUE-associated ON; I-ON, isolated ON; mg, milligram; dl, deciliter;
µl, microliter; kg, kilogram; SID, semel in die (once daily); BID, bis in
die (twice daily); NMO, neuromyelitis optica; NMOSD, neuromyelitis optica
spectrum disorders; MS, multiple sclerosis; GFAP, glial fibrillary acidic protein;
AQP-4, aquaporin 4; MOG, myelin oligodendrocyte glycoprotein; ADEM,
acute disseminated encephalomyelitis; OPC, oligodendrocyte precursor cells;
OCB, oligoclonal bands; TG-2, transglutaminase 2; MOGAD, MOG-IgG-
associated disorder.
This study focuses on canine ON of presumed immune-
mediated etiology including isolated and MUE-associated forms.
The clinicopathologic presentation, advanced imaging findings,
treatment, and outcome in dogs with ON have been previously
described (1, 3–12, 16, 39, 40, 56). While prognostic factors
have been reported in dogs with MUE, such factors have not
been specifically investigated with a focus on ON (10, 57–60).
The purpose of this study is to identify prognostic factors for
recovery of vision in canine ON. The authors hypothesized that
a shorter duration of blindness prior to immunosuppressive
therapy and a lower cerebrospinal fluid (CSF) total nucleated cell
count (TNCC) are associated with complete recovery of vision.
MATERIALS AND METHODS
This study followed a retrospective multi-center design. The
clinical records of dogs diagnosed with ON were reviewed. The
database of three referral veterinary hospitals was accessed from
2003 to 2018: Pride Veterinary Centre; Queen Mother Hospital
for Animals, Royal Veterinary College; Small Animal Teaching
Hospital, University of Liverpool. Ethical approval was granted
at all institutions involved.
Dogs of any age, sex and breed were included if all of
the following criteria were met: (a) physical and neurological
assessment at presentation and follow-up examinations at least
21 days apart; (b) presence of visual disturbance assessed by a
neurology and/or ophthalmology clinician (resident, residency-
trained or board-certified) based on the ability to navigate
successfully obstacles; (c) advanced imaging of the head (CT or
MRI) classified as adequate in terms of sequence/plane selection
and diagnostic quality and interpreted by a board-certified
neurologist and radiologist; (d) fundoscopic and/or advanced
diagnostic imaging findings consistent with ON; (e) a maximum
of 3-week history of visual disturbance; (f) absent/incomplete
menace response and/or absent/incomplete pupillary light reflex
(PLR) in the affected eye/s that could not be explained by other
clinicopathologic or imaging findings. Cases were excluded if
one or more of the following criteria were met: (a) intracranial
or extracranial neoplasia (suspected or confirmed); (b) ocular
inflammation or infection; (c) presumed toxin exposure or
adverse reactions to medications; (d) systemic or CNS infection
suspected based on positive serological and/or CSF screening
tests; (e) suspected or witnessed ocular and/or orbital trauma;
(f) incomplete clinical records at presentation or follow-up
examinations; (g) follow-up period<21 days.
Data retrieved from medical records included patient
signalment (age, sex, breed, neuter status), clinical history,
presenting complaint, clinical, neurological and ophthalmologic
examination, therapeutic protocol, and outcome. Further
diagnostic tests included CBC, serum biochemistry profile,
urinalysis, electroretinography (ERG), CSF analysis, and
screening tests for infectious diseases. Protein concentration in
CSF >27 mg/dl for cerebellomedullary and TNCC >5 cells/µl
were classified as increased (61).
Fundoscopic findings were classified as consistent with ON
when signs of papillitis and/or neuroretinitis were detected.
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Papillitis was characterized by a swollen optic disc with blurred
margins, loss of the physiologic cup, raised blood vessels on the
disc surface, hemorrhages and/or exudates involving the optic
disc. Neuroretinitis was diagnosed when the extension of these
pathological changes to the retina occurred (1, 3, 4, 7, 12).
Magnetic resonance imaging of the head was performed
using four 1.5 Tesla Magnets (Intera and Ingenia CX,
Philips Medical Systems, Eindhoven, the Netherlands; Siemens
Magnetom Essenza, Frimley, United Kingdom; HDe, GE
Healthcare, United Kingdom). Selected sequences included
T2-weighted, Fluid-Attenuated Inversion Recovery (FLAIR),
Short Tau Inversion Recovery (STIR), Gradient Echo, pre-
and post-contrast T1-weighted, and post-contrast T1-weighted
fat suppression images. Sagittal, dorsal, transverse and oblique
dorsal and sagittal planes were evaluated. CT of the head was
performed using a 16-slice CT scanner (Mx8000 IDT, Philips,
Best, the Netherlands). Post-contrast images were acquired
using Gadoterate Meglumine (Dotarem R©, Guerbet, UK) for
MRI and Iohexol (Omnipaque R© 300, GE Healthcare, UK) for
CT. Magnetic resonance imaging findings were assessed for
optic nerve lesions consistent with ON as follows: presence of
hyperintense signal on T2-weighted, FLAIR and STIR images;
enhancement on T1-weighted post-contrast images and/or T1-
weighted fat suppression post-contrast images; enlargement of
the optic nerve or optic chiasm with no significant mass
lesion; loss of the subarachnoid CSF signal of the intra-orbital
optic nerve segment secondary to thickening of the optic
nerve; optic nerve head swelling (7, 12, 13, 62, 63). Computed
tomography findings of suspected ON consisted of the following
abnormalities involving the optic nerve: contrast uptake; optic
nerve head swelling; enlargement of the optic nerve or optic
chiasm with no significant mass lesion (64–67).
Dogs were divided into two groups: presumptive MUE-
associated ON with multifocal CNS disease (MUE-ON) and
presumptive isolated ON (I-ON). Dogs with I-ON were
characterized by the absence of clinical or advanced imaging
findings involving the CNS outside the optic nerve. Dogs with
MUE-ON had additional neurological deficits and/or advanced
imaging findings involving the CNS outside the optic nerve.
Group allocation did not depend on the results of CSF analysis.
Dogs receiving only corticosteroids were assigned in the
monotherapy group and those treated with any additional
immunosuppressive medication in the polytherapy group. The
outcome was based on comparing the following parameters
before and after treatment: the ability to navigate obstacles
successfully, menace response, and PLR. The menace response
was subjectively assessed as complete, incomplete, or absent.
The PLR was classified as reactive (PLR present) referring to
a complete or an incomplete reflex and non-reactive (PLR
absent) referring to an absent reflex. Dogs were divided into
two groups based on their visual outcome: (a) complete recovery
of vision; (b) no or incomplete recovery of vision. Complete
recovery of vision was characterized by the following: successful
navigation of obstacles and normal vision reported by the owner;
complete menace response in both eyes; complete PLR in both
eyes. Incomplete recovery of vision was characterized by at
least one of the following: partial improvement in navigating
obstacles and partial improvement of vision reported by the
owner; improved but incomplete menace response in at least
one eye; improved but incomplete PLR in at least one eye. No
recovery of vision was characterized by all of the following:
no improvement of the ability to navigate obstacles and no
improvement of vision reported by the owner; no improvement
of the menace response with or without deterioration in either
eye; no improvement of the PLR with or without deterioration
in either eye. Dogs with no recovery of vision that further
deteriorated as well as the prevalence of relapses in all dogs were
recorded. Follow-up period was defined as the number of days
from the first presentation until the final re-examination and
communication with the owner and/or the referring veterinary
surgeon. Follow-up data included clinical and neurological
findings as well as telephone communications with owners and
referring veterinary surgeons.
Statistical analysis was carried out using Graph Pad Prism
7.00 (GraphPad Software, La Jolla, California USA). Tests for
normality were performed on each group (D’Agostino and
Shapiro-Wilk Tests). Individual datasets were compared using
the Chi-squared test, Fisher’s exact test and the Mann- Whitney
U-test. For multiple comparisons with parametric datasets, the
one-way analysis of variance (ANOVA) was performed, and for
non-parametric datasets, the Kruskal-Wallis test was performed
to test for independence. Dunn’s multiple comparisons test was
used to analyze differences between specific groups. For all data,
averages are expressed as median with interquartile range with
significance set at p< 0.05.
RESULTS
Case Selection
A total of 46 dogs with ON were identified. Nine cases were
excluded due to insufficient follow-up (two dogs), inadequate
clinical information (one dog), suspected infectious diseases (two
dogs), suspected intracranial (three dogs), and extracranial (one
dog) neoplasia. Eleven dogs did not meet the inclusion criteria
due to the lack of advanced diagnostic imaging or negative
MRI/CT and fundoscopy results. The remaining 26 dogs with
ON fulfilled the inclusion criteria and were included in the study.
Signalment
The median age at presentation was 47.5 months (range 7–
132 months, mean 49.2 months). Males represented 58% of the
population (15 dogs) and females 42% (11 dogs), with eight
spayed female and 10 neutered male dogs. The most prevalent
dog breed was French Bulldog with 11 cases (42%), followed
by Jack Russell Terrier with three cases, Shih Tzu and Lhasa
Apso with two cases each and one dog from the following
breeds: Patterdale Terrier, Bedlington Terrier, Finnish Lapphund,
English Springer Spaniel, Border Collie, Boston Terrier, West
Highland White Terrier, and Cairn Terrier. The prevalence of
French Bulldogs in the general hospital canine population of two
participating referral centers providing 22 out of 26 cases was
1.7%. This information was not available from the third referral
hospital. Median body weight at presentation was 10.8 kg (range
6–20.7 kg, mean 11.6 kg). Age at presentation had a significant
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TABLE 1 | Clinicopathologic findings with prognostic value in 26 dogs with ON.
Recovery of vision Statistically significant prognostic factors
Age (months) Dogs with reactive PLR (%) Dogs with fundoscopic lesions (%)* CSF TNCC (cells/µl)
Median Mean Range Median Mean Range
Complete recovery 21.5 26 7–62 4/6 (67%) 1/5 (20%) 1.5 4.5 0–20
Incomplete/no recovery 58.5 56.2 11–132 2/20 (10%) 18/18 (100%) 20 150 0–1,065
p-value 0.038a 0.013b 0.0006b 0.022a
PLR, pupillary light reflex; CSF, cerebrospinal fluid; TNCC, total nucleated cell count; µl, microliter.
*Fundoscopic examination was performed in 23 out of 26 dogs.
aMann-Whitney test.
bFisher’s exact test.
effect on outcome (p = 0.038) (Table 1). The younger the dog
was at presentation, themore likely a complete recovery of vision.
No statistically significant association was identified between
complete recovery of vision and breed, gender, neuter status,
or weight.
Clinical Signs
Ten dogs (38%) had partial loss of vision while 16 (62%) were
completely blind at presentation. One dog had enucleation of
one eye before ON; thus, a total of 51 eyes were assessed
out of which 48 were classified as affected. A reactive PLR
was observed in 19 out of 48 affected eyes (40%; nine eyes
with complete PLR, 10 eyes with incomplete PLR) while 29
eyes (60%) were characterized by a non-reactive PLR. Menace
response was abnormal in 45 out of 48 affected eyes (94%)
with an absent response in 43 and an incomplete response in
two eyes. Except for two affected eyes in two different dogs,
the menace response was always characterized by either the
same or a worse degree of deficit compared to the PLR of the
same eye at presentation. Visual deficits were predominantly
bilateral (22 dogs; 85%). Themedian duration of blindness before
immunosuppressive treatment was 6 days (range 1–21 days,
mean 7.3 days) and the median delay of treatment (time from
presentation to immunosuppressive treatment) was 1 day (range
0–15 days, mean 1.8 days). The presence of a reactive PLR (p =
0.013) at presentation was statistically associated with complete
recovery of vision (Table 1). There was no statistically significant
influence identified of the severity of menace response deficit,
laterality of ON, severity of visual disturbance and duration of
blindness before immunosuppressive treatment.
Investigations
Infectious disease screening included CSF PCR for Toxoplasma
gondii, Neospora caninum, Borrelia burgdorferi, Ehrlichia canis,
Ehrlichia ewingii, Anaplasma phagocytophilum, Anaplasma
platys, and Canine Distemper Virus; serum antibody titers for
Toxoplasma gondii, Neospora caninum, Leptospira spp.; latex
cryptococcal antigen test (LCAT) and in-clinic Idexx SNAP
4Dx Plus test (SNAP 4Dx Plus, IDEXX Laboratories, UK)
for Ehrlichia canis, Ehrlichia ewingii, Borrelia burgdorferi,
Anaplasma phagocytophilum and Anaplasma platys. All but five
dogs were tested for infectious diseases and were negative.
Fundoscopic examination was performed in 23 cases (88%),
and lesions consistent with ON were found in 19 out of 23
(83%). No abnormality was identified on fundoscopy in the
remaining four dogs (17%). Electroretinography was performed
in nine cases, including the four dogs with normal fundoscopy
and was within normal limits. The absence of fundoscopic lesions
was significantly associated with complete recovery of vision
(p= 0.0006) (Table 1).
Advanced imaging of the head was performed in all cases
(MRI in 25 dogs, CT scan in one dog). Lesions identified on
advanced imaging were positive for ON in 21 dogs (81%). All
five dogs with no optic nerve lesions on MRI/CT were diagnosed
with MUE, but concurrent ON was suspected clinically and was
confirmed on fundoscopy. Thirteen out of 19 dogs (68%) with
MUE-ON showed no clinical signs referring to CNS disease
outside the optic nerve on history or neurological examination.
The absence of optic nerve lesions onMRI/CT was not associated
with complete recovery of vision.
All dogs had cerebellomedullary CSF analysis performed. One
case was excluded from further analysis of TNCC and protein
concentration due to severe blood contamination. This case was
classified as having normal CSF despite the iatrogenic blood
contamination. For the remaining 25 cases, 17 (68%) showed
abnormalities. Fourteen dogs (56%) had an increased protein
concentration (median 30 mg/dl, mean 56 mg/dl, range 28–
490) and 13 (52%) an elevated TNCC (median 20 cells/µl,
mean 137 cells/µl, range 7–1,065). No statistically significant
association was identified between CSF protein concentration
and complete recovery. The CSF TNCC was significantly
associated with complete recovery of vision (p = 0.022). The
lower the TNCC the higher were the chances for complete
recovery of vision (Table 1).
Diagnosis
Diagnosis of presumptive ON was reached based on the
identification of both fundoscopic and advanced imaging
findings consistent with ON in 14 dogs (54%), advanced imaging
findings alone in seven dogs (27%) and fundoscopic findings
alone in five dogs (19%). The diagnosis was supported by the
clinical/neurological examination findings, CSF analysis, ERG,
and negative infectious diseases tests. Nineteen cases (73%)
were diagnosed with MUE-ON and seven (27%) with I-ON. No
Frontiers in Veterinary Science | www.frontiersin.org 4 November 2019 | Volume 6 | Article 415
Posporis et al. Prognostic Factors in Optic Neuritis
TABLE 2 | Comparison of statistically significant clinicopathologic differences between dogs with MUE-ON and I-ON.
Type of ON Statistically significant clinicopathologic differences between groups
Median age (months) Number of neutered dogs (%) CSF TNCC (cells/µl)
Median Mean Range
MUE-ON 59 16/19 (84%) 20 128 0–1065
I-ON 19 2/7 (29%) 2 82 0–560
p-value 0.046a 0.014b 0.030
MUE-ON, meningoencephalitis of unknown etiology-associated optic neuritis; I-ON, isolated optic neuritis; CSF, cerebrospinal fluid; TNCC, total nucleated cell count; µl, microliter.
aMann-Whitney test.
bFisher’s exact test.
association was found between the diagnosis of I-ON or MUE-
ON and complete recovery of vision. Dogs with I-ON were
significantly younger (p = 0.046) and had lower CSF TNCC
(p = 0.030) compared to the MUE-ON group, which appeared
to have significantly more neutered dogs (p = 0.014) (Table 2).
Dogs with fundoscopic lesions consistent with papillitis and/or
neuroretinitis were statistically more likely to have a non-reactive
PLR (p = 0.040), complete loss of vision (p = 0.024), higher
CSF protein concentration (p = 0.029) and TNCC (p = 0.033)
compared to dogs with retrobulbar ON.
Treatment
Twelve dogs had received treatment before referral, but none
was immunosuppressed. No history of any medications given
prior to referral was available in two cases. Eyedrops (Maxitrol,
Pred Forte, Azopt) were used in five dogs, non-steroidal anti-
inflammatories in six (meloxicam, carprofen, robenacoxib), a
single anti-inflammatory dose of dexamethasone in one dog,
antibiotics in three (amoxicillin-clavulanic acid, trimethoprim
sulfadiazine), and chlorphenamine, paracetamol, tramadol, and
imepitoin in one case each. The median duration of anti-
inflammatory therapy before presentation in these seven cases
was 3 days (range 1–14 days, mean = 5.4 days). Their CSF
TNCC at presentation was normal in two (<5 cells/µl) and
increased in five dogs (median= 41 cells/µl, mean= 116 cells/µl,
range seven to 404 cells/µl). After diagnosis, all dogs received
immunosuppressive therapy on a tapering regimen consisting of
at least corticosteroids (prednisolone or dexamethasone followed
by prednisolone). One or more adjunctive immunosuppressive
medications were used in 22 dogs (85%) for at least one
month: cytosine arabinoside (18 dogs), cyclosporine (four dogs),
leflunomide (one dog), and lomustine (one dog). Antibiotics
(clindamycin and doxycycline) were used briefly in three dogs
and were discontinued once negative results from infectious
diseases were received. No difference in outcome was identified
between dogs treated with monotherapy or polytherapy.
Follow-up, Outcome, and Relapses
Follow-up ranged from 21 to 1,901 days (median 230; mean
496). Complete recovery of vision was achieved in six out of 26
dogs (23%). Incomplete or no recovery of vision was recorded
in 20 dogs (77%) with 11 (42%) showing signs of incomplete
improvement and nine (35%) having no recovery. Only one out
of seven dogs pre-treated with anti-inflammatory medications
prior to referral achieved complete recovery of vision. No
deterioration after immunosuppressive treatment was seen in any
of the cases. Seven out of nine dogs with no recovery of vision
were diagnosed with MUE-ON. While their vision remained
unchanged, improvement of their MUE-associated clinical signs
was reported. Nine dogs (35%) had at least one relapse from 102
to 827 days after the initial diagnosis of ON. Seven out of these
nine dogs were diagnosed with MUE-ON and two with I-ON.
DISCUSSION
This study identified factors associated with visual recovery in
26 dogs with ON. A younger age, a reactive PLR, the absence
of fundoscopic lesions, and a lower CSF TNCC at presentation
were statistically associated with complete recovery of vision.
To the best of our knowledge, no similar studies investigating
prognostic factors in dogs with ON currently exist. In people with
ON, prognosis mainly depends on the underlying subtype of ON,
and diagnostic accuracy is highly relevant for approach to clinical
management (68) (Table 3). Visual recovery is slightly worse in
patients with MS-associated ON compared to those with isolated
disease, but both have an overall positive long-term outcome
(72). Atypical forms of ON such as NMO/NMOSD have a poorer
prognosis and more recurrent attacks (68, 73–75). Severe loss of
visual acuity at presentation (76, 77), specific ethnicity/race (78),
late treatment (79), bilateral ON (80), involvement of the intra-
canalicular part of the optic nerve onMRI, absence of retrobulbar
pain (77), and older age at onset (76) were associated with poorer
outcomes yet not all authors validated these results (78, 80).
The younger the dog was at presentation the higher were the
chances for complete recovery of vision in this study population.
Similarly, a recent publication investigating canine MUE showed
that younger age at onset was associated with longer survival,
but none of these dogs were diagnosed with concurrent ON
(58). Still, other authors failed to repeat this finding (11, 57).
In human medicine, pediatric ON is characterized by better
recovery of visual acuity and lower annual relapse rates (76,
77, 81–83). In contrast, younger-onset patients with NMO from
the United Kingdom have a higher risk for visual disability
(73). Interestingly, dogs with I-ON were significantly younger
compared to those with MUE-ON. Considering the correlation
between humanmedicine data and our results, a specific pediatric
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TABLE 3 | Severity and prognosis in human immune-mediated ON-associated
diseases (68–71).
ON-associated
disease
Severity Prognosis
MS-associated
ON
Solitary
(monophasic)
isolated ON
Usually unilateral mild to
moderate visual loss and
mild periocular pain
Spontaneous improvement in
>90% of patients
NMO-associated
ON
Usually bilateral severe
visual loss
Transverse myelitis
Incomplete recovery
Attacks of ON and/or
transverse myelitis recur in
>85% of patients with
paralysis or blindness seen in
50% of cases within 5 years
Chronic relapsing
inflammatory optic
neuropathy
Usually bilateral severe
visual loss with persistence
of pain after onset of
blindness
Steroid-responsive (long-term)
Frequent relapses when
treatment is
reduced/interrupted
ADEM-associated
ON
High incidence in pediatric
population
Encephalomyelitis with
severe bilateral optic neuritis
in up to 15% of patients.
Complete recovery in 56–94%
Multiphasic ADEM in 0–23%
Monophasic ADEM followed
by recurrent ON in 0–9%
Residual visual deficits
are common
ON, optic neuritis; MS, multiple sclerosis; NMO, neuromyelitis optica; ADEM, acute
disseminated encephalomyelitis.
ON phenotype could be considered in young dogs. The question
also arises whether aging influences recovery and remyelination
of the optic nerves or if benign phenotypes of ON are more
common in younger dogs. Generally, remyelination decreases
with age, as seen with any other regenerative process (84).
Activation, recruitment, and differentiation of oligodendrocyte
progenitor cells (OPC) decline with age (85–90). In addition,
regulation of OPC behavior is influenced by signaling molecules
secreted by macrophages or by phagocytized myelin debris
containing inhibitors of OPC differentiation (91, 92). These
processes are delayed with age (89, 93). Myelin debris clearance
and remyelination are greater in younger animals due to more
performant circulating monocytes (84). In clinical practice, the
influence of aging could have an impact on demyelinating
diseases such as ON.
A high number of French Bulldogs (42%) was recorded
in our study. The popularity of the breed could have biased
this finding but the prevalence of French Bulldogs in the
general canine population of the referral hospitals providing
22 out of 26 cases was only 1.7%. While MUE/ON represents
25% of encephalopathies in French Bulldogs (94), no data
on familial inheritance is currently available in this breed.
In people, genetic factors play a role in the development of
MS and NMO, both of which are associated with ON but
have significantly different prognosis (95–97). Interestingly, the
strongest genetic risk in MS is related to the human leukocyte
antigen (HLA) class II—DRB1 region which reflects similarities
with the canine NME model association to the dog leucocyte
antigen class II (DLA II) (98–101). Another common functional
genetic variant between dogs and people was found outside the
HLA II region, within the IL7R gene (96, 101). Most of the
French Bulldogs included in our study (73%) were diagnosed
with presumptive MUE, but the lack of histopathological
confirmation prevented further categorization into NME or
other types of MUE. The identification of predisposing genetic
factors could achieve a more specific classification of canine
ON sub-types. However, it is currently unclear if this could
also result in prognostic contributions. Comprehending the
differences in outcome and clinical course between distinct
human ON-associated disorders, one can also suspect the clinical
relevance of a potential sub-categorization of canine ON in
achieving accurate prognostication. The association between
genetic predisposition and prognosis remains to be explored in
future studies.
The impression that ON requires immediate
immunosuppressive treatment predominates among
practitioners. Surprisingly, the duration of blindness prior
to immunosuppressive therapy was not statistically associated
with the visual outcome in our study population; thus, one of our
hypotheses was rejected. This finding can have clinical relevance
in the decision-making process for the treatment of canine ON.
One of the most common dilemmas clinicians face during this
process is whether to start treatment immediately or to wait for
results of infectious disease testing. Indeed, knowing if delaying
treatment influences the prognosis or not can have an impact
on clinical decision-making. In our study population, the six
dogs with complete recovery of vision received treatment 2 days
(1 case), 7 days (2 cases), 12 days (1 case), 13 days (1 case),
and 21 days (1 dog) after onset of blindness but still achieved
complete recovery of vision. The possibility that treatment prior
to presentation could have influenced the outcome by improving
the chances of recovery was considered. However, only one
out of seven dogs that were pre-treated with anti-inflammatory
medications before referral achieved complete recovery of vision.
Moreover, our data of seven pre-treated dogs showed elevation
of CSF TNCC in five dogs, and thus it could not be concluded
that pre-treatment prior to presentation has a protective effect or
influence on the final outcome. Immunosuppressive medications
were not used in any of the included cases prior to diagnosis
of ON. Although our results suggest that duration of blindness
prior to treatment does not appear to influence outcome, these
findings require validation by larger sample size studies and
changes in current practice cannot be recommended at this
stage. Furthermore, the maximum duration of blindness prior
to immunosuppressive treatment was 3 weeks, and this limited
our ability to investigate the prognosis in dogs with longer
treatment delay. Contrariwise, considering that factors such as
presence of PLR, normal fundoscopy, and lower CSF TNCC
were associated with complete recovery of vision, it is possible
that parameters related to the severity of the disease have more
prognostic value than its actual duration. In people with ON,
one study reported improved visual acuity in Thai patients with
isolated ON treated within 8 days from onset (79). In another
study, early treatment (within 7 days from onset) was associated
with better short-term visual outcomes in people with severe
acute ON, but long-term visual acuity was not influenced by the
timing of treatment (102).
Frontiers in Veterinary Science | www.frontiersin.org 6 November 2019 | Volume 6 | Article 415
Posporis et al. Prognostic Factors in Optic Neuritis
TABLE 4 | Biomarkers with prognostic value in people with ON
(72, 81, 112, 118–139).
Biomarker Contribution in diagnosis Prognostic value
AQP-4 Ab Positive in NMO
Negative in MS
Distinction of NMO from MS with
a sensitivity of 68–91% and
specificity of 85–99%
More severe and relapsing ON
Higher rate of conversion to
NMO within 1 year
Poorer visual outcomes
compared to other phenotypes
OCB Positive in 20–30% of patients
with NMO, 6–13% in MOGAD
and 80% in MS.
Spontaneous recovery in MS-ON
Lipid-specific oligoclonal IgM
bands could indicate a more
severe clinical course and predict
earlier onset of MS
MOG Ab Diagnosis of MOGAD
Rare in adults with MS
Absent in AQP-4-seropositive
NMO patients
Seropositivity in children with
AQP-4-seronegative NMOSD,
recurrent ON, transverse myelitis
and multiphasic or
monophasic ADEM
Similar to NMO phenotype but
better visual outcomes reported
Negative and positive clinical
courses reported
Recurrent attacks of ON
Gly-R Ab Currently unknown
Positive in adults with ON
Relapsing isolated ON
NMDA-R
Ab
NMDA-R encephalitis
Positive in some adults with ON
Monophasic episodes of
NMOSD, brainstem or multifocal
demyelinating syndromes
GFAP Astrocytic biomarker of highly
active inflammation in NMO
GFAP concentration is believed
to be higher in NMO than in MS
Correlation with clinical severity
was demonstrated between CSF
GFAP and NMO relapses but
also between serum GFAP and
relapsing-remitting MS
Interleukin-
6
Interleykin-
6-receptor
Notable increases in CSF
interleukin-6 and soluble
interleukin-6 receptor
concentration identified in NMO
Currently unknown
MRZ
reaction
Positive in MS (78%)
Rare in most patients with
atypical types of ON such as
NMO, ADEM and
autoimmune encephalitis
Spontaneous recovery in MS-ON
AQP-4, aquaporin 4; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG-IgG-
associated disorder; Ab, antibody; Gly-R, glycine receptor a1 subunit; NMDA-R, N-
methyl-D-aspartate receptor; OCB, oligoclonal bands; NMOSD, neuromyelitis optica
spectrum disorders; NMO, neuromyelitis optica; MS, multiple sclerosis; ADEM, acute
disseminated encephalomyelitis; ON, optic neuritis; GFAP, glial fibrillary acidic protein;
MRZ, measles, rubella and varicella zoster virus.
The presence of PLR was associated with complete recovery
of vision in this study. The PLR can be a marker of optic nerve
dysfunction (103). In people, quantitative PLR assessments show
significantly decreased results in acute ON (104) and correlate
with the severity of damage (105, 106). However, qualitative
PLR examination is a subjective evaluation of the degree of
pupillary constriction, which depends on the experience of the
examiner and light intensity (107, 108). Our results showed that
the presence of PLR is not uncommon among dogs with ONwith
40% of affected eyes having a reactive PLR. Similarly, reactive
PLR (incomplete or intact) was previously reported in 21% of
eyes with immune-mediated ON (5). Hence, the presence of
PLR should not drive clinicians away from the neuroanatomical
diagnosis of optic neuropathy.
The absence of fundoscopic lesions was associated with
complete recovery of vision. As long as other pathognomonic
features of ON are present and primary retinal pathology is
ruled out, the lack of fundoscopic abnormalities is indicative of
retrobulbar ON (1, 7). Based on previous reports (5, 7) and in
corroboration with our data, it appears that retrobulbar ON has
a low prevalence in dogs. In people, retrobulbar ON occurs in
two-thirds of patients with typical ON (109). In our study, dogs
with papillitis/neuroretinitis were statistically more likely to have
a non-reactive PLR, complete loss of vision, higher CSF protein
concentration and TNCC. It is possible that the involvement of
the optic disc/retina is associated with more severe or irreversible
lesions compared to a retrobulbar localization. We could also
speculate that retrobulbar ON represents a less aggressive ON
phenotype characterized by better visual outcomes. However,
the absence of fundoscopic lesions is not a specific feature
of certain ON phenotypes in people (75, 110). In addition,
optic disc swelling accompanied by mild initial visual acuity
loss was associated with better short-term outcomes in people
with bilateral acute ON, and this somewhat contradicts our
findings (80).
A lower CSF TNCC was associated with complete recovery of
vision in our study. Five out of six dogs with complete recovery
of vision had a normal CSF TNCC, and these findings support
one of our hypotheses. Smith and colleagues reported abnormal
CSF analysis in 41 and 91% of dogs with MRI/CT-confirmed I-
ON andMUE-ON, respectively. Similar to our findings (Table 2),
this study reported that the CSF TNCC was significantly higher
in dogs with MUE-ON (median = 146 cells/µl) than in those
with I-ON (median = five cells/µl) (5). In canine MUE, a higher
CSF TNCC was associated with shorter survival (58), whereas
this finding was dismissed by an earlier study (11). In people,
the presence of CSF pleocytosis is not a pathognomonic feature
of specific ON subtypes, but a greater pleocytosis is expected
with NMO than MS (111–113). The degree of pleocytosis could
correspond to the severity of inflammation and subsequent
damage which then could have an impact on visual outcome.
However, the significance of pleocytosis in canine immune-
mediated CNS diseases, including ON, is currently unknown.
Interestingly, dogs with steroid-responsive meningitis arteritis
can present with prominent pleocytosis but prognosis for
recovery remains excellent with appropriate therapy (114–116),
whereas up to 57% of dogs with MUE can have normal CSF
cytology (48, 117) and this does not necessarily reflect a better
prognosis (11, 57, 60).
In search of prognostic factors in human ON, the value of
serum/CSF biomarkers in the classification of this syndrome in
pathogenetically distinct phenotypes cannot be underestimated.
Accurate diagnosis and differentiation between ON sub-types
have been facilitated by the discovery of such markers (118–
122) (Table 4). This is closely related to prognosis due to their
well-known differences in outcome, clinical course, and response
to various therapies (2, 68–71, 140, 141). Even within the same
ON phenotype, specific biomarkers have been demonstrated to
predict the clinical course of the disease. For example, oligoclonal
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immunoglobulin G andM bands were shown to predict the onset
of conversion of isolated ON toMS (123). In veterinarymedicine,
disease-specificmarkers and their potential prognostic value have
not yet been validated. Auto-antibodies against astrocytes such
as anti-glial fibrillary acidic protein (GFAP) (142, 143) and anti-
transglutaminase-2 (TG-2) antibodies (144) have been identified
in dogs with MUE and particularly NME. Nonetheless, there
is currently no evidence available linking the presence of these
biomarkers to canine ON and its outcome.
The presence of optic nerve lesions on MRI/CT was not
associated with the outcome in this study. While MRI appeared
to have high sensitivity in identifying lesions suggestive of ON,
19% of included dogs had noMRI lesions of the optic nerve. This
has been previously described in dogs with ON (5), and a normal
MRI was also reported in 24% of dogs with inflammatory CSF
(145). The overall agreement between neurological examination
and MRI findings can be as low as 60% (48, 146). Likewise,
subclinical brain lesions were identified in 68% of our patients
with MUE-ON. This demonstrates the limited sensitivity of the
clinical assessment in identifying mild encephalopathic signs
in visually impaired dogs (48, 146). It further highlights the
importance of MRI in the diagnosis of ON-associated diseases
as the presence of parenchymal brain lesions may have an
impact on the general prognosis and survival. Moreover, MRI
is superior compared to CT in detecting such lesions. Thus it
cannot be excluded that the one dog with CT-confirmed I-ON
could have beenmisclassified as brain parenchymal lesions might
have been missed.
Dogs with ON are traditionally treated with long-term
immunosuppressive protocols. This is not a surprise considering
the potential life-threatening implications of MUE and its
frequent association with ON. In human patients, therapeutic
requirements vary depending on the underlying etiology.
In MS-associated ON, faster recovery can be seen with
corticosteroids, but the long-term outcome is positive even
without immunosuppressive therapy (76, 147). Chronic relapsing
inflammatory optic neuropathy and NMO require high-dose
and prolonged corticosteroid treatment (2). The investigation
of canine ON phenotypes not requiring immunosuppression is
highly problematic due to ethical considerations of not treating a
condition that is frequently associated with MUE.
Visual outcome was generally poor in this study as only 23% of
included dogs achieved significant visual recovery. Similar results
were reported by Smith and colleagues, with only 17% of dogs
with ON achieving complete recovery of vision (5). Recurrence
was recorded in 35% of our cases and is a known phenomenon
in canine MUE and ON (5, 9, 12, 39). In people, recurrence
occurs in 28% of patients within 5 years and 35% within 10
years (148, 149). The concurrent diagnosis of underlying diseases
such as NMO and MS, the presence of unilateral ON and the
use of relatively low initial glucocorticoid dosage were associated
with higher recurrence rates (150). In our study, the concurrent
diagnosis of MUE and the laterality of ON did not have an impact
on visual outcomes. The association of different parameters with
relapsing disease was not statistically investigated.
Limitations of this study are its retrospective multicenter
nature and small sample size, especially of the complete recovery
group. Fundoscopic examination was not performed in all dogs
and this inevitably decreased the total number of cases used
for statistical evaluation of fundoscopy as a prognostic factor.
All 4 cases with normal fundoscopic examination achieved full
recovery of vision and this was statistically significant in our
population. Nevertheless, the limited sample size of dogs with
fundoscopic examination remains a limitation. Additionally, the
involvement of multiple clinicians inevitably results in some
degree of subjective outcome assessment. This is probably most
prominent in the assessment of vision and degree of PLR
deficit. In an attempt to decrease the degree of subjective PLR
assessment, the result of this test was classified as reactive or
non-reactive in our study. Accurate evaluation of vision in
dogs is challenging. Future studies should combine behavioral
assessment of visual acuity (151) and clinical testing with more
objective methods such as visual evoked potentials (VEP).
This is performed in people with ON to assess conduction
recovery along the visual pathway and represents a valuable
tool in interpreting relapses (152). The use of VEP in dogs
has been reported, and results are reliable and reproducible
(153–155). Other diagnostic modalities are also gaining interest
in clinical and research settings in human medicine. Optical
coherence tomography is a high-resolution imaging technology
with applications inmonitoring the course ofMS and the severity
of optic nerve damage (156, 157). This technique has been
described in veterinary literature (158), but its clinical application
in canine ON is still premature.
A high degree of confidence for the diagnosis of ON was
reached in most of our cases. Nonetheless, considering the lack
of histopathological confirmation of MUE, other differentials
cannot be entirely ruled out, and this represents another
limitation. The overlap between the clinical profiles of ON
and ischemic optic neuropathy in human patients (159) could
also occur in dogs, and this disorder should be considered as
a differential in canine patients with sudden-onset blindness.
Ischemic optic neuropathy was reported in a dog with acute
onset pre-chiasmatic blindness and was diagnosed on MRI with
diffusion-weighted (DWI) and apparent diffusion coefficient
(ADC) map sequences. Additional findings of a mesencephalic
infarct and hypertension were detected and supported the
diagnosis (160). Diffusion-weighted and ADC map sequences
were not performed in our study, which could represent a
limitation. However, MRI and/or fundoscopic features of ON
together with other clinicopathologic findings supported the
diagnosis in our patients. Moreover, the presence of optic
nerve abnormalities on routine MRI sequences is significantly
associated with the diagnosis of ON rather than ischemic optic
neuropathy in people (161, 162).
Therapeutic protocols varied between the studied dogs, and
this is another limitation as it might have influenced the outcome.
One could further argue that infectious diseases could have
been missed as not all pathogens previously linked to ON were
investigated. However, none of the included dogs deteriorated
after immunosuppressive treatment. Infectious diseases are
generally uncommon in our geographic region, and studies
failed to identify infectious agents in CSF and brain samples
of dogs with MUE (163–166). In contrast, sporadic evidence of
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specific pathogens has been reported in dogs withMUE, but their
implication in the development of the disease warrants further
investigation (165, 167–169).
In conclusion, our study identified prognostic factors that
were associated with complete recovery of vision in 26 dogs with
ON. A larger cohort of dogs is required to determine whether
our findings are robust and whether any additional measurable
parameters aid accurate prognostication. The validation of
prognostic factors in canine ON could assist clinicians in
improving current clinical practice. Finally, the apparent
clinicopathologic and prognostic variability between different
ON-associated diseases in people exposes the importance of
developing an accurate etiopathogenic classification of distinct
ON subtypes in dogs.
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